Non-response group (n = 16) | Response group (n = 15) | p value | |
---|---|---|---|
T1WI | 1.000 | ||
Iso-intensity | 1 (6.3%) | 1 (6.7%) | |
Mild hypo-intensity | 15 (93.8%) | 14 (93.3%) | |
T2WI | 1.000 | ||
Iso-/mild hypo-intensity | 7 (43.8%) | 7 (46.7%) | |
Mild hyper-intensity | 9 (56.3%) | 8 (53.3%) | |
Morphology | 0.037 | ||
Regular | 9 (56.3%) | 14 (93.3%) | |
Irregular | 7 (43.8%) | 1 (6.7%) | |
Tumour margins on T2WI | 0.394 | ||
Well defined | 2 (12.5%) | 4 (26.7%) | |
Ill defined | 14 (87.5%) | 11 (73.3%) | |
Tumour margins on T1WI | 0.473 | ||
Well defined | 5 (31.3%) | 7 (46.7%) | |
Ill defined | 11 (68.6%) | 8 (53.3%) | |
Tumour margins after enhancement | 0.073 | ||
Well defined | 6 (37.5%) | 11 (73.3%) | |
Ill defined | 10 (62.5%) | 4 (26.7%) | |
Peripheral delayed enhancement of tumour | 0.135 | ||
Invisible | 13 (81.3%) | 8 (53.3%) | |
Visible | 3 (18.8%) | 7 (46.7%) | |
Central delayed enhancement of tumour | 0.473 | ||
Invisible | 8 (50.0%) | 5 (33.3%) | |
Visible | 8 (50.0%) | 10 (66.7%) | |
Necrosis of tumour | 0.172 | ||
Absence | 11 (68.8%) | 14 (93.3%) | |
Presence | 5 (31.3%) | 1 (6.7%) | |
Peripancreatic infiltration | 0.012 | ||
Invisible | 4 (25.0%) | 11 (73.3%) | |
Visible | 12 (75.0%) | 4 (26.7%) | |
Peripancreatic blood vessel invasion | 1.000 | ||
Invisible | 10 (62.5%) | 10 (66.7%) | |
Visible | 6 (37.5%) | 5 (33.3%) | |
Artery invasion | 0.654 | ||
Invisible | 14 (87.5%) | 12 (80.0%) | |
Visible | 2 (12.5%) | 3 (20.0%) | |
Vein invasion | 0.704 | ||
Invisible | 10 (62.5%) | 11 (73.3%) | |
Visible | 6 (37.5%) | 4 (26.7%) | |
Pancreatic duct dilatation | 0.704 | ||
Absence | 6 (37.5%) | 4 (26.7%) | |
Presence | 10 (62.5%) | 11 (73.3%) | |
Atrophy of upstream pancreas | 0.458 | ||
Absence | 9 (56.3%) | 11 (73.3%) | |
Presence | 7 (43.8%) | 4 (26.7%) | |
Retention cyst formation | – | ||
Absence | 16 (100.0%) | 15 (100.0%) | |
Presence | 0 (0.0%) | 0 (0.0%) |